As genomic sequencing expands, so does our knowledge of the link between genetic variation and disease. Deeper catalogs of variant frequencies improve identification of benign variants, while sequencing affected individuals reveals disease-associated variation. Accumulation of human genetic data thus makes reanalysis a means to maximize the benefits of clinical sequencing. We implemented pipelines to systematically reassess sequencing data from 494 individuals with developmental disability. Reanalysis yielded pathogenic or likely pathogenic (P/LP) variants that were not initially reported in 23 individuals, 6 described here, comprising a 16% increase in P/LP yield.
As genomic sequencing expands, so does our knowledge of the link between genetic variation and disease. Deeper catalogs of variant frequencies improve identification of benign variants, while sequencing affected individuals reveals disease-associated variation. Accumulation of human genetic data thus makes reanalysis a means to maximize the benefits of clinical sequencing. We implemented pipelines to systematically reassess sequencing data from 494 individuals with developmental disability. Reanalysis yielded pathogenic or likely pathogenic (P/LP) variants that were not initially reported in 23 individuals, 6 described here, comprising a 16% increase in P/LP yield.
We also downgraded 3 LP and 6 variants of uncertain significance (VUS) due to updated population frequency data. The likelihood of identifying a new P/LP variant increased over time, as~22%
of individuals who did not receive a P/LP variant at their original analysis subsequently did after 3 years. We show here that reanalysis and data sharing increase the diagnostic yield and accuracy of clinical sequencing.
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| INTRODUCTION
Whole-genome sequencing (WGS) and whole-exome sequencing (WES) are increasingly used clinically, particularly for rare disease diagnosis.
WGS/WES uncovers pathogenic or likely pathogenic (P/LP) variants in 20% to 60% of sequenced patients, [1] [2] [3] [4] leaving many patients without a relevant genetic finding. Although these individuals may have diseases that are non-genetic or result from complex genetic effects, incomplete knowledge of genetic variation likely prevents identification of many P/LP variants. Systematically reanalyzing data over time may prove useful, as accumulated knowledge-that is new publications, updated population frequencies, improved clinical variant databases, and data sharing among researchers-may facilitate new discoveries. [5] [6] [7] We sought to systematically reanalyze WES/WGS data from probands with developmental delay and/or intellectual disability (DD/ID) enrolled in the Clinical Sequencing Exploratory Research (CSER) project at HudsonAlpha. 8 An initial reanalysis effort was described in an analysis of the first 371 affected probands, 8 but an expanded and improved reanalysis pipeline, including new findings, approaches, and implications, is presented here. Table S1 and Appendix S1, Supporting Information 5 Sequence data for consenting participants is available at dbGAP. 13 Appendix S1 provides additional details.
| MATERIALS AND METHODS

| Study overview
| Uniparental disomy analysis
Uniparental disomy (UPD) was called using UPDio. 14 Copy number variant (CNV) calls (Appendix S1) were masked and not considered by UPDio.
| SLC1A4 analysis
DNA and RNA isolation, cDNA synthesis, PCR, and qPCR were conducted with standard protocols (Appendix S1). Graphpad Prism version 7.0c (GraphPad Software, La Jolla, CA, USA) was used for graphing and statistics.
3 | RESULTS
| New findings
Based on the success of our initial reanalysis efforts, 8 we sought to improve and expand our strategy. We have subsequently identified P/LP variation in 6 additional probands ( Table 1) . Two of these "upgrades" resulted from recent publications and two from GeneMatcher 11 collaborations (Table 1) . One of these variants (FGF12, NM_004113.5:c.145G>A, (p.Arg114His)) is a recurrent de novo variant now seen in two unrelated probands in our cohort. 8, 15 In each of these four cases, the variation was in a gene not previously associated with disease and was originally classified as a non-returnable variant of uncertain significance (VUS). After data supporting gene-disease associations became available, application of ACMG criteria led to classification of these variants as P/LP (Table 1 ) and returned to families.
In one case, we identified a single nucleotide variant (SNV) and a CNV within SLC1A4, associated with an autosomal recessive neurodevelopmental disorder (MIM:616657). 16 Initially (June 2015), no returnable variation was found in this proband. However, upon reanalysis, a paternally inherited pathogenic missense variant 16 was found using updated ClinVar information. A targeted search for a second variant in SLC1A4 revealed a maternally inherited 782-bp deletion (Table 1) . We confirmed the presence of this deletion in genomic DNA from the proband and mother ( Figures S1 and S2 ). While this variant does not change SLC1A4 transcript levels, it does result in skipping of exon 6 (Figures S1 and S3) and is predicted to lead to an in-frame deletion of 65 amino acids encompassing two transmembrane domains. This CNV was only identified in the proband by one of the four algorithms in our pipeline and was completely missed in the mother; curation of unfiltered CNVs coupled to manual inspection of reads in both the samples was required. Had we not found the previously reported missense variant, or lacked phenotype data suggesting the relevance of SLC1A4, this CNV would have been missed.
In addition to manual reanalysis in light of new data, we also implemented methods to detect UPD. While UPD, especially heterodisomy, often goes unnoticed, it can cause DD/ID when imprinted regions are affected. [17] [18] [19] We found two cases of disease-associated UPD, both affecting chromosome 15 (Table 1) . Clinical methylation analyses confirmed the first. Clinical methylation analyses were recommended for the second but not performed. a Original scores for SNV/CNVs based on retroactive scoring using ACMG criteria for a gene of uncertain significance. None of the variants in this table were returned to probands at time of the first analysis, nor was ACMG scoring or criteria explicitly used at that time.
b Note that this variant was previously reported with our initial study findings, 8 although the variant was recently found in one additional unrelated proband in our study, represented here.
c ACMG scoring criteria do not apply to UPD.
| Downgrades
In addition to searching for new P/LP variation, we also reanalyzed all previously returned variants, leading to downgrades of nine variants in seven individuals ( Table 2) . Six of these variants were originally classified as VUSs and 3 of them were considered LP. All downgrades resulted from the addition of data in the ExAC/gnomAD databases. 6 Variants present at non-trivial frequencies in these databases are unlikely to be dominant, highly penetrant DD/ID variants. 6 Similarly, variation that is homozygous or hemizygous at non-trivial frequencies is unlikely to cause recessive or X-linked disease. Although reanalysis did uncover new P/LP variation in 3 of these 7 probands, upgrade and downgrade decisions were made independent of one another.
| Likelihood of variant upgrade over time
We conducted WES on the first 127 probands of this study and switched to WGS for all subsequent probands (Table S1 ). We measured P/LP rates separately for WES and WGS, both before and after reanalysis (Table S2 ). Although the initial P/LP rate for WGS (26.2%) was greater than that for WES (22.0%), reanalysis yielded an 11.0%
increase in the P/LP rate for WES and only 1.6% increase for WGS.
To further refine this comparison, as all WES cases were trios, we also restricted calculations for WGS to trios, and found the P/LP rate in (Table 3 , Appendix S1).
| DISCUSSION
Accumulation of genetic knowledge suggests that reanalysis of sequencing data may lead to discovery of novel medically relevant
variants and to refinement of initial variant interpretations. Our reanalysis efforts thus far have led to identification of 22 P/LP variants in 23 probands in a cohort of 494 total patients. These affect~6% of probands who originally received either a VUS or no returnables and represent a 16% increase in the total P/LP yield. Other groups have also reported success with reanalysis, with upgrade rates from 10% to 36%. 7, 20 The ACMG has published guidelines for the interpretation of sequence variants, 12 and it is important to note that the changed interpretations in our study did not result from altered application of criteria, but rather new evidence supporting (or refuting) pathogenicity.
Three of the downgrades resulted in a change from LP to likely benign. The ACMG suggests that an LP designation represents pathogenicity with 90% confidence. 12 In our case, these 3 downgrades represent 9% of all variants initially determined to be LP, suggesting an empirical error rate similar to the conceptual target established by the ACMG. As population variant frequency databases expand, reanalysis of previously reported variants will continue to be necessary.
Based on our experience with reanalysis, we suggest the following framework:
1. If reanalysis has never been conducted on WES/WGS data, it should be performed, even in the absence of annotation or pipeline updates. New P/LP variation may be discovered simply by reviewing new literature during manual curation.
2. WES data lacking P/LP variation should be reanalyzed before performing WGS, especially for data over 2 years old. of the individuals in our cohort that lack a P/LP variant harbor a variant within a gene that has been submitted to GeneMatcher; 79% (34/43) of these genes have at least preliminary matches. 6 . Time since initial analysis should inform the reanalysis strategy. If WGS/WES data were analyzed within the past year, reanalysis yield will be small-in our case, only 1%. However, datasets first analyzed over two years ago should be prioritized for reanalysis, consistent with observations from others. 7, 20 We also note that timing of analysis is a major factor to consider when evaluating the overall yield rates, particularly when focused on comparisons of technologies that have changed over time. For example, while
we believe a number of factors support the benefits of WGS over WES for rare disease diagnosis (eg, improved CNV detection, more uniform depth of coverage, etc.), the tendency for WGSbased analyses to be more recent than that for WES-based analyses must be accounted for when comparing P/LP variant yields.
In summary, our data strongly support the benefits of systematic reanalysis of WES/WGS data. Such efforts lead to substantial increases in P/LP variant discoveries, while simultaneously reducing false positive P/LP rates. Thus, reanalysis can substantially improve the accuracy and benefits of clinical sequencing. Abbreviations: DD/ID, developmental delay and/or intellectual disability; P/LP, pathogenic or likely pathogenic.
